Since 2005, adults in our center with standard-risk ALL, as defined according to the criteria of the United Kingdom Medical Research Council Adult Leukemia Working Party and Eastern Cooperative Oncology Group (MRC UKALL XII/ECOG) E2993 protocol28, 29, have received induction, intensification, consolidation, and maintenance therapy using the MRC UKALL XII/ECOG E2993-based regimen, including E. coli-asparaginase or PEG-asparaginase as asparaginase (Table 1). Here, ASPG is linked to acute lymphoblastic leukemia.